Plaintiffs Include Thousands of Women, Men and Children Who Have Suffered Serious Gastrointestinal Side Effects, Including Stomach Paralysis
Walsh Law PLLC, a boutique law firm actively involved in numerous mass tort litigation matters nationwide, announced today that Founder Alex Walsh has been appointed to the Plaintiffs’ Executive Committee in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability multidistrict litigation (MDL No. 3094).
“I am honored to be included in this distinguished group of attorneys, who bring a diverse set of strengths, experiences, and perspectives to this important litigation,” said Alex Walsh, Founder of Walsh Law. “I would also like to express my gratitude to Judge Pratter for her deliberate and thoughtful approach in working with the plaintiffs’ counsel to reach this point. The drug companies will have formidable legal teams working on their behalf, making it crucial to assemble a panel that can adequately represent the interests of the women, men, and sadly, even children who have been harmed by these powerful drugs. We are now turning our full attention toward litigating this case.”
In an order issued on May 8th, U.S District Judge Gene E.K. Pratter of the Eastern District of Pennsylvania appointed four Co-Lead Counsel for the Plaintiffs, two members of the Plaintiffs’ Executive Committee, and ten members of the Plaintiffs’ Steering Committee.
The Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) MDL involves allegations that the Defendants, pharmaceutical companies Novo Nordisk & Eli Lilly and Company, failed to adequately warn users about the complications and devastating side effects associated with the use of its popular diabetes and weight loss drugs, including Ozempic, Wegovy, and Rybelsus.